Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1

Nicole D Fer¹, Robert H Shoemaker² and Anne Monks*¹

Abstract

Background: Preclinical toxicity of adaphostin has been related to oxidative stress. This study investigated the regulatory mechanism underlying adaphostin induction of heme oxygenase 1 (HMOX1) which plays a significant role in modulation of drug-induced toxicity in the non-small cell lung cancer cell line model, NCI-H522.

Methods: The transcriptional response of NCI-H522 to adaphostin prominently involved oxidative stress genes, particularly HMOX1. Reactive oxygen species (ROS) involvement was additionally established by generation of ROS prior to modulation of adaphostin-toxicity with antioxidants. To identify up-stream regulatory elements of HMOX1, immunofluorescence was used to evaluate nuclear translocation of the transcription factor, NF-E2-related factor 2 (Nrf2), in the presence of adaphostin. The PI3-kinase inhibitor, wortmannin, was employed as a pharmacological inhibitor of this process.

Results: Generation of ROS provided a substantial foundation for the sensitivity of NCI-H522 to adaphostin. However, in contrast to leukemia cell lines, transcriptional response to oxidative stress was associated with induction of HMOX1, which was dependent on nuclear translocation of the transcription factor, Nrf2. Pretreatment of cells with wortmannin inhibited translocation of Nrf2 and induction of HMOX1. Wortmannin pretreatment was also able to diminish adaphostin induction of HMOX1, and as a consequence, enhance the toxicity of adaphostin to NCI-H522.

Conclusions: Adaphostin-induced oxidative stress in NCI-H522 was mediated through nuclear translocation of Nrf2 leading to upregulation of HMOX1. Inhibition of Nrf2 translocation by wortmannin inhibited this cytoprotective response, and enhanced the toxicity of adaphostin, suggesting that inhibitors of the PI3K pathway, such as wortmannin, might augment the antiproliferative effects of adaphostin in solid tumors that depend on the Nrf2/ARE pathway for protection against oxidative stress.

Background

Adaphostin (NSC 680410) is the adamantyl ester of tyrophostin AG957 (NSC 654705) and inhibits the p210bcr-abl tyrosine kinase in CML, but is also toxic against cells without the fusion protein[1]. The toxicity of adaphostin against leukemia cells has been shown to require generation of reactive oxygen species (ROS) [2] and involve iron homeostasis [3], and most work on this compound has focused on hematologic malignancies. However, in vitro testing of adaphostin in the NCI-60 cell line panel indicated that several solid tumor cancer cell lines also demonstrated considerable sensitivity to adaphostin, indicating there may be a role for adaphostin in treatment of solid tumors. The prostate tumor cell line, PC3 was published as a model to demonstrate signaling cascades involved in adaphostin induced growth inhibition and cell cycle arrest [4], but this cell line is an order of magnitude more resistant than the lung tumor model NCI-H522 to the growth inhibitory effects of the drug in the NCI-60 human tumor cell line screen (data on DTP website: http://dtp.nci.nih.gov/). An early report showed an anti-tumor effect on an orthotopic glioblastoma model U87, in combination with the Flt-1/Fc chimera [5], and more recent evaluation of adaphostin activity in glioblastoma cell lines identified a high level of HMOX1 induc-
tion [6]. HMOX1 is the first and rate limiting step in the degradative pathway of heme, but has also been recognized as an integral part of a cytoprotective mechanism against oxidative stress [7,8]. HMOX1 is a target gene of the basic leucine zipper (bZIP) transcription factor, nuclear factor erythroid 2-like 2, Nrf2 (NFE2L2), a central regulator of cellular oxidative stress response and represents an adaptive response that increases cell resistance to oxidative injury. Nrf2 is readily induced in response to ROS through the Nrf2-ARE pathway which transcriptionally up regulates antioxidant genes in order to protect cells [9]. Nrf2 is regulated through PI3K/AKT pathway [10-12], and translocated into the nucleus where it binds to the antioxidant responsive element (ARE) which results in activation of this enhancer element and initiates the transcription of genes encoding phase II detoxification enzymes. These enzymes [8,9] initiate an antioxidant response, which can be beneficial for cancer prevention [13]. However, the Nrf2-ARE pathway has recently been implicated in chemoresistance and the feasibility of Nrf2 inhibition as a strategy for sensitizing cells to chemotherapeutics was demonstrated [13-15]. HMOX1 upregulation has been identified in the adaphostin response in adherent cell lines, but not in hematopoietic cell line models, and it appears that adaphostin activates a different oxidative stress response in solid tumor models than in leukemia models. Thus, we have investigated the mechanism behind HMOX1 induction in the adaphostin-sensitive lung tumor cell line NCI-H522, and demonstrated an enhancement of adaphostin toxicity following inhibition of Nrf2 nuclear translocation with the PI3K inhibitor wortmannin.

**Methods**

**Drugs and Cell Culture**

Adaphostin (NSC 680410) and wortmannin (NSC 221019) were obtained from the repository of the National Cancer Institute's Developmental Therapeutics Program (Rockville, Maryland). Desferrioxamine (DFX) and N-acetyl-cysteine (NAC) were purchased from Sigma® (St. Louis, Missouri). NCI-H522, and the leukemia cell lines, (Jurkat, HL60 and K562) were obtained from the NCI-60 Human Tumor Cell Line Screen (National Cancer Institute-Frederick, Maryland).

**Transcriptional Profiling: Microarray Technology**

Human OperonV2, 20K arrays, (National Cancer Institute microarray facility/Advanced Technology Center, Gaithersburg, Maryland) were utilized according to published protocols http://madb.nci.nih.gov/. Using competitive hybridization of treated versus untreated samples chemically coupled to a Cy®3 or Cy®5 fluorescently labeled dye (Amersham Biosciences, Little Chalfont Buckinghamshire, England) and fluorescence was read on a GenePix 4100A microarray scanner purchased from Axon Instruments (Union City, California). Data was analyzed using the Axon GenePix Pro 4.1 software and data and image files were then uploaded to the National Cancer Institute/Cancer Center for Research Microarray Center mAdB Gateway for analysis and comparison of multiple arrays.

**Real Time RT-PCR**

Five hundred nanograms of total RNA for each sample was reverse transcribed using the GeneAmp PCR System 9700 and TaqMan® Reverse Transcription Reagents kit. Quantitative real time PCR reactions were conducted and measured using the ABI Prism™ 7700 Sequence Detection System and TaqMan® chemistries using published primers. Samples were tested in triplicate wells for the genes of interest and for the endogenous control, 18 S. Data was analyzed using the comparative Ct method as described in the Perkin Elmer User Bulletin #2 (ABI Prism’ 7700 Sequence Detection System, 1997) and expressed as a fold induction of the gene in the adaphostin treated samples compared to the untreated control samples, and significant differences were calculated using a paired two sample t-test.

**Western Blot**

Whole cell and nuclear extracts were made for protein analysis by western blot. Nuclear extracts were prepared from cells in 100 mm dishes that were lysed using a hypotonic buffer. The nuclei were pelleted at 13,000 x g for 15 minutes, and then after the supernatant was aspirated, the nuclei were lysed using 1x RIPA lysis buffer (Upstate, Lake Placid, New York) containing protease inhibitors (Roche, Mannheim, Germany). Protein was quantitated using Bradford Protein Assay (Bio-Rad Laboratories, Hercules, California), and approximately 50 μg of each sample was resolved by SDS-PAGE on 10% Tris glycine gels (Invitrogen, Carlsbad, California) and probed with anti-Nrf2 (Santa Cruz Biotechnology, Santa Cruz, California) and anti-HMOX1 antibodies (Affinity Bioagents, Golden, Colorado). Proteins were visualized using chemiluminescence and imaged using a Kodak™ X-OMAT 2000A Processor (Rochester, New York).

**Measurement of adaphostin-induced ROS**

Intracellular ROS were measured after 2 and 4 hours exposure to 1 μM adaphostin using 2’,7’-dichlorofluorescein diacetate (DCFH-DA, Sigma®; St. Louis, Missouri). Cells were incubated for 3 minutes with 10 μM DCFH-DA, lysed and centrifuged. The fluorescence was read on a Wallac Victor 2 1420 Multilabel Counter (PerkinElmer, Waltham, Massachusetts) at excitation of 485 nm and emission of 535 nm and protein normalized using Bradford Protein Assay. Results were expressed as percentage...
increase compared to control and significant differences calculated using a two sample t-test assuming equal variances.

Modulation of growth inhibition
Cells were inoculated onto 96 well plates (20,000 cells/ well) and preincubated with DFX (100 μM), NAC (25 mM) or wortmannin (250 nM) prior to addition of adaphostin for a further 96 h incubation. Growth inhibition was assessed by alamarBlue (Sigma’, St. Louis, Missouri), fluorescence was read on a Tecan Ultra plate reader (509 nm excitation and 520 nm emission); and results analyzed using the average percent treated/control (%T/C), with significant differences calculated using a paired two sample t-test.

Immunofluorescence
Cells were plated in Lab-Tek chamber slides (60,000 cells/ well) and treated 4-6 hours with 1 μM adaphostin, or pretreated 30 minutes with 500 nM wortmannin, followed by 4 hour incubation with 1 μM adaphostin where indicated. Cells were fixed using cold methanol; permeabilized with 0.1% Triton X-100; blocked in 20% goat serum; incubated with Nrf2 antibody overnight; labeled using FITC-conjugated secondary antibody; and nuclei were counterstained with DAPI. Prolong Anti-Fade (Invitrogen, Carlsbad, California) was used to mount coverslip overnight. Samples were visualized using a Leitz Laborlux D fluorescence microscope and images were captured by Leica DFC420 camera and analyzed in Adobe Photoshop Elements 2.0.

Results
Although hematopoietic malignancies have been the major target of pre-clinical studies with adaphostin [1-3,5,16-19], NCI-H522, a solid tumor-derived, non-small lung cancer cell line, was also very sensitive to adaphostin in the NCI-60 human tumor cell line screen. From four independent experiments in the NCI-60 screen, the 50% growth inhibitory concentration (GI50) for the 6 leukemia cell lines ranged from 40 nM -630 nM, and the GI50 for NCI-H522 was 79 nM, which was 10-fold more sensitive than the average response for the whole cell line panel (762 nM) (data available at: http://dtp.nci.nih.gov/ for NSC 680410). Transcriptional profiling of NCI-H522 in response to 1 μM adaphostin showed one of the most highly upregulated genes to be HMOX1 (11.3 +/- 2.1 (SD) fold increase after 24 h), which encodes for an enzyme that protects against oxidative stress [7,8]. This increase in HMOX1 expression was confirmed using Q-RT/PCR which also corroborated the lack of significant change in expression of the NRF2 gene (figure 1A). Moreover, a small but significant increase in the Nrf2 transcriptional target gene, NAD(P)H dehydrogenase, quinone 1 NQO1 was observed although there was no change in another Nrf2 target, the catalytic subunit of glutamate-cysteine ligase GCLC (figure 1A). A significant increase in ROS production was observed as early as 2 h after adaphostin treatment which is confirmation of the presence of drug-induced oxidative stress (figure 1B). Heme oxygenase 1, the protein encoded by HMOX1, was shown to be increased by adaphostin treatment (1 μM) at a later time point than HMOX1, being only slightly increased after 6 h, but highly expressed after 24 h (figure 1C). These data are consistent with the 10 μM adaphostin-induced heme oxygenase 1 expression reported in glioblastoma cell lines, which did not appear until after 8-24 h [6]. This adaphostin-induced HMOX1 upregulation in NCI-H522 cells and glioblastoma cell lines [6] is in contrast to the response of hematologic cell lines where we have previously reported the major transcriptional response involved >10-fold induction of genes encoding for both heavy and light ferritin polypeptides (FTH and FTL) [3]. Moreover, even after treatment with 10 μM adaphostin,
leukemia cell lines (Jurkat, HL60 and K562) showed no increase in HMOX1 expression on the cDNA arrays after 6 h incubation (average expression (n = 3) = 1.24 +/- 0.7(SD), 1.35 +/- 0.39(SD) and 1.16 +/- 0.28(SD) respectively), compared to a 7.4 and 30.8 -fold increase in HMOX1 expression in NCI-H522 cells when measured on the same type of arrays following treatment with 1 and 4 μM adaphostin for 6 h. Evidence that ROS are an important factor in determining sensitivity of NCI-H522 to adaphostin was demonstrated by the ablation of adaphostin toxicity by the anti-oxidant, N-acetyl-cysteine in a manner similar to that shown for the leukemia cell line Jurkat (figure 2). However, in contrast to Jurkat, the iron chelating agent desferrioxamine (100 μM) did not attenuate adaphostin toxicity in the NCI-H522 cell line (figure 2), and there was no measurable increase in either ferritin gene (array expression (n = 5): FTH = 1.09 +/- 0.15 (SD); FTL = 1.02 +/- 0.24(SD)), indicating that release of excess free iron is not involved in the NCI-H522 response to adaphostin. Thus, these data substantiate the difference between response of a solid tumor and that which we have shown in leukemia cell lines [3].

As the induction of HMOX1 appears to be unique to the response of solid tumors [6], we investigated the role of its putative regulatory transcription factor, Nrf2, in adaphostin treated NCI-H522 cells. Nrf2 protein, when activated is rapidly translocated into the nucleus, and in adaphostin-treated NCI-H522 cells, Nrf2 was rapidly induced in the nuclear fraction within 2-6 h, although there was no detectable Nrf2 expression in the cytosolic fraction over this time (figure 3A). Furthermore, translocation of Nrf2 from the cytoplasm into the nucleus by adaphostin can be visualized using immunohistochemistry (figure 3B) where nuclear localization of Nrf2 after 4 h and 6 h incubation of NCI-H522 cells with 1 μM adaphostin was apparent compared to the more diffuse Nrf2 distribution in untreated cells.

Wortmannin, a PI3 kinase inhibitor, has been shown to inhibit Nrf2 translocation into the nucleus [20,21] and was successfully used as a tool to inhibit adaphostin-induced, nuclear translocation of Nrf2 (figure 4). Pretreatment (30 minutes) of NCI-H522 cells with 500 nM wortmannin was effective at inhibiting adaphostin-induced nuclear localization of Nrf2, although wortmannin alone had no effect. In addition, under these conditions when Nrf2 translocation was inhibited with wortmannin, expression of Nrf2 target genes HMOX1 and NQO1 were significantly (p < 0.01) reduced by ~50% and ~35% respectively after 6 h adaphostin incubation, and though not significant, there was a trend to a reduced expression after 4 h incubation (figure 5). There was no significant change in GCLC expression which is consistent with the lack of induction of this gene with adaphostin, and implicates Nrf2 as the regulator of adaphostin-induced HMOX1.

Finally, figure 6 shows that when HMOX1 induction was diminished via inhibition of Nrf2 nuclear translocation, there was an augmentation of adaphostin toxicity with a reduction of the GI50 from 342 nM to 273 nM, with the most significant effect (p < 0.01) at the lower concentrations of adaphostin.

**Discussion**

Adaphostin, a tyrphostin-like kinase inhibitor whose toxicity to tumor cell lines is a function of its ability to induce oxidative stress and cause a redox imbalance in cells [2,22-25]. In hematologic tumor cell lines, we have previously shown that iron homeostasis and up-regulation of ferritin genes were an integral part of the response to adaphostin [3]. In contrast, evaluation of the transcriptional response of a solid tumor derived, non-small cell lung cancer cell line, NCI-H522, which is equally sensitive to adaphostin as the hematologic cell lines indicated...
that the HMOX1 gene was the most highly up-regulated gene, and there was very little modulation of the ferritins. The up-regulation of HMOX1 in solid tumor derived models, is consistent with data published for glioblastoma cell lines [6] suggesting that these cell lines may utilize different pathways to handle the adaphostin induced oxidative stress. Moreover, the growth inhibitory curve of adaphostin in NCI-H522 was completely ablated by pretreatment with the antioxidant NAC, but not with desferrioxamine indicating that despite the role of HMOX1 in generating free iron from heme, iron homeostasis is not an important feature of the response to ROS generated by adaphostin. HMOX1 is a stress-inducible enzyme that is 

Figure 3 Adaphostin (ADA) induces nuclear localization of Nrf2 protein (A) NCI-H522 cells were incubated for 2 h, 4 h and 6 h with 1 μM of ADA; nuclear and cytosolic proteins were resolved by Western blot analysis as indicated in the Materials and Methods (NS, non-specific band was used for normalization). Data are representative of three independent experiments. (B) Confirmation of ADA-induced Nrf2 translocation into the nucleus. NCI-H522 cells were incubated for 4 h or 6 h with 1 μM ADA and were stained with Nrf2 and FITC-conjugated antibodies. Nuclei were counter-stained with the fluorescence dye DAPI. Data are representative of three independent experiments.

Figure 4 Wortmannin inhibits adaphostin (ADA)-induced translocation of Nrf2 into the nucleus. NCI-H522 cells were pretreated 30 minutes with 500 nM wortmannin where indicated, followed by incubation with 1 μM ADA and stained with Nrf2 and FITC-conjugated antibodies. Nuclei were counter-stained with the fluorescence dye DAPI. Data are representative of two independent experiments.

Figure 5 Adaphostin (ADA) induction of HMOX1 and NQO1 is inhibited by the presence of wortmannin (WTM). NCI-H522 cells were pretreated 30 minutes with 500 nM WTM, followed by incubation with 1 μM ADA. Expression of HMOX1, NQO1 and GCLC was measured by quantitative real-time reverse transcription-PCR after a further 1, 4 and 6 h and expressed as a percentage of the control ADA-induced gene expression measured at that time in the absence of WTM pretreatment. There was a significant decrease in 6 h ADA-induced HMOX1 and NQO1 expression after wortmannin pretreatment (n = 3; +/- SD; ** indicates p < 0.01)
most commonly regulated by the basic leucine zipper transcription factor Nrf2, which is a regulator of multiple antioxidant genes [12]. Dramatic induction of HMOX1 appears to be stimulated by adaphostin in this cell line. Another well documented target of Nrf2, NAD(P)H dehydrogenase, quinone 1 (NQO1) was also induced to a lesser extent but there was no evidence for regulation of gamma-glutamylcysteine synthetase (GCLC), which is consistent with data from cultured RPE cells where modulation of Nrf2 activity led to selective down regulation of only certain phase 2 detoxification genes, and not all stimuli resulted in all genes being modulated [11]. Adaphostin triggered the translocation of Nrf2 protein into the nucleus, as measured both by an increase in nuclear protein and immunofluorescence. Nrf2 translocation into the nucleus has been shown to be prevented by the PI3 kinase inhibitor, wortmannin [11,21]. Pretreatment with wortmannin was clearly able to reduce adaphostin-induced Nrf2 nuclear translocation in NCI-H522, and there was a significant decrease in HMOX1 induction after 6 h adaphostin treatment. Thus, these data confirm in a sensitive solid tumor model, NCI-H522, that the major cause of adaphostin toxicity was through generation of ROS, which is the widely accepted model of toxicity for hematologic malignancies [2,3,25]. However, unlike hematologic malignancies, adaphostin initiated an antioxidant response in NCI-H522 cells through up-regulation of HMOX1. The transcriptional increase was initiated through Nrf2, following its translocation into the nucleus, and could be inhibited by wortmannin, implicating the PI3K pathway in the activity of adaphostin. Nrf2 has been identified as a master redox switch involved in the activity of cytoprotective phytochemicals with chemopreventive activity against cancer [26], and plays an important role in the defense against oxidative stress [27]. However, a ‘dark side’ of Nrf2 has recently been recognized [15], identifying it as responsible for resistance against chemotherapy, thus making Nrf2 a potential target to improve activity of certain chemotherapeutic agents [13,28,29].

Conclusions
Targeting of the Nrf2 transcription factor may be important for drugs whose major mechanism of action was through the generation of ROS (e.g. adaphostin), as there is evidence for a selective killing of tumor versus normal cells [30], and inhibition of the antioxidant, protective role of Nrf2 may increase the toxic potential of such agents. When NCI-H522 cells were preincubated with wortmannin to inhibit Nrf2 translocation, there was a significant increase in adaphostin toxicity. This data may provide a rationale for successful combinations of adaphostin, or other pro-oxidant agents, with inhibitors of the PI3K pathway as modulators of Nrf2 antioxidant activity.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
NDF was responsible for all experimental data and helped draft the manuscript. RHS aided coordination of the study and helped draft the manuscript. AM conceived of the study, participated in its design and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was supported by the Developmental Therapeutics Program in the Division of Cancer Treatment and Diagnosis of the National Cancer Institute.

Author Details
1. Laboratory of Functional Genomics, SAIC-Frederick Inc., NCI-Frederick, (1050 Boyles Street), Frederick, (21702), USA and 2. Screening Technologies Branch, NCI-Frederick, (1050 Boyles Street), Frederick, (21702), USA

Received: 4 May 2010 Accepted: 9 July 2010
Published: 9 July 2010

References
1. Svingen PA, Tefferi A, Kotke-Texas, Kaur G, Narayan VL, Saussville EA, Kaufmann SH: Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res 2000, 6:237-249.
2. Chandra J, Hackbart J, Le S, Loegering D, Bone N, Bruzek LM, Narayan VL, Adjei AA, Kay NE, Tefferi A, Karp JE, Saussville EA, Kaufmann SH: Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood 2003, 102:4512-4519.
3. Hose C, Kaur G, Sausville EA, Monks A. Transcriptional profiling identifies altered intracellular lable iron homeostasis as a contributing factor to the toxicity of adaphostin: decreased vascular endothelial growth factor secretion is independent of hypoxia-inducible factor-1 regulation. *Cancer Res* 2005, 65:6370-6381.

4. Mukhopadhyay I, Sausville EA, Doroshow JH, Roy KK. Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways. *J Biol Chem* 2006, 281:17330-173344.

5. Avramis IA, Christodouloupolos G, Suzuki A, Laug WE, Gonzalez-Gomez L, McNamara G, Sausville EA, Avramis VI. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. *Cancer Chemother Pharmacol* 2002, 50:479-489.

6. Long J, Manchanda T, Ban K, Gao S, Miller C, Chandra J. Adaphostin cytotoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1. *Cancer Chemother Pharmacol* 2007, 59:527-533.

7. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase-1. *Pharmacol Rev* 2008, 60:79-127.

8. Keyse SM, Tyrrell RM. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. *Proc Natl Acad Sci USA* 1989, 86:99-103.

9. Rushmore TH, Morton MR, Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. *J Biol Chem* 1991, 266:11632-11639.

10. Nakao K, Yano H, Fukuhara Y, Takashima T, Wada-Izoe K, Nakashima K. PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by heme in human neuroblastoma cells. *FEBS Lett* 2003, 546:181-184.

11. Wang L, Chen Y, Sterberg P, Cai J. Essential roles of the PI3 kinase/Akt pathway in regulating Nrf2-antioxidant deficient functions in the RPE. *Invest Ophthalmol Vis Sci* 2008, 49:1671-1678.

12. Martin D, Rojo AL, Salinas M, Diaz R, Gallardo G, Alam J, De Galarreta CM, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E, Feinstein E, Biswal S. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 inhibits Nrf2-dependent protection from oxidative stress deleteriously affects cell survival. *Proc Natl Acad Sci USA* 2005, 102:143-148.

13. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. *Pharmacol Res* 2008, 58:262-270.

14. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E, Feinstein E, Biswal S. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. *Cancer Res* 2008, 68:7975-7984.

15. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, Wong PK, Zhang DD. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. *Carcinogenesis* 2008, 29:1235-1243.

16. Barnes DJ, De S, van Hermegarten P, Moravcsik E, Melo JV. Adaphostin-induced oxidative stress overcomes BCR/Abl mutation-dependent and -independent imatinib resistance. *Blood* 2006, 107:2501-2506.

17. Orsolic N, Golemovic M, Quintas-Cardama A, Scappini B, Manshouri T, Chandra J, Basic I, Giles F, Kantarjian H, Verstovsek S. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. *Cancer Sci* 2006, 97:692-696.

18. Yu C, Rahmany M, Almenara J, Sausville EA, Dent P, Grant S. Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process. *Oncogene* 2004, 23:1364-1376.

19. Lee JM, Hanson JM, Chu WA, Johnson JA. Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. *J Biol Chem* 2001, 276:20011-20016.

20. Kang KW, Lee SJ, Park JW, Kim SG. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-κB-related factor 2 through actin rearrangement in response to oxidative stress. *Mol Pharmacol* 2002, 62:1001-1010.

21. Dasmahapatra G, Nguyen TK, Dent P, Grant S. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. *Leuk Res* 2006, 30:1263-1272.

22. Le SB, Halier MK, Buhrow S, Wang Q, Flatten K, Pediatadaks P, Bible KC, Lewis LD, Sausville EA, Pang YP, Ames MM, Lermasters JJ, Holmuhamedov EI, Kaufman SH. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. *J Biol Chem* 2007, 282:8860-8872.

23. Shanafelt TD, Lee YK, Bone ND, Strege AK, Narayanan VL, Sausville EA, Geyer SM, Kaufmann SH, Kay NE. Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. *Blood* 2005, 105:2099-2106.

24. Stocklin LH, Bumke MA, Yu SX, Webb SP, Collins JR, Hollingshead MG, Newton DL. Proteomic analysis identifies oxidative stress induction by adaphostin. *Clin Cancer Res* 2007, 13:3667-3681.

25. Surh YJ, Kundu JK, Nrk. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. *Planta Med* 2008, 74:1526-1539.

26. Li W, Khor TO, Xu C, Shen G, Jeong WS, Yu S, Kong KN. Activation of Nrf2-antioxidant signaling attenuates NFκB-mediated inflammatory response and elicits apoptosis. *Biochem Pharmacol* 2008, 76:1485-1491.

27. Akhdar H, Loyer P, Rauch C, Corlu A, Guillouzo A, Morel F. Involvement of Nrf2 activation in resistance to S-fluorouracil in human colon cancer HT-29 cells. *Eur J Cancer* 2009, 45:2219-2227.

28. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, Kikuchi N, Sato H, Sakamoto T, Hizawa N, Ito K, Yamamoto M. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. *Clin Cancer Res* 2009, 15:3423-3432.

29. Verjux J, Pedrosa RC, Beck R, Dejeans N, Taper H, Calderon PB. In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells. *Curr Med Chem* 2009, 16:1821-1830.